[{"id":"40e9c584-14da-4391-b55e-d2b5af41ff2b","acronym":"MK-1308-001","url":"https://clinicaltrials.gov/study/NCT03179436","created_at":"2021-01-17T17:28:19.740Z","updated_at":"2024-07-02T16:35:09.610Z","phase":"Phase 1/2","brief_title":"Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)","source_id_and_acronym":"NCT03179436 - MK-1308-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • BRAF • ALK • CTLA4","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ALK translocation","tags":["EGFR • BRAF • ALK • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • quavonlimab (MK-1308) • quavonlimab/pembrolizumab (MK-1308A)"],"overall_status":"Completed","enrollment":" Enrollment 413","initiation":"Initiation: 07/02/2017","start_date":" 07/02/2017","primary_txt":" Primary completion: 04/08/2024","primary_completion_date":" 04/08/2024","study_txt":" Completion: 04/08/2024","study_completion_date":" 04/08/2024","last_update_posted":"2024-04-16"},{"id":"b7ba04ad-2e05-4858-90e2-5ecabf721773","acronym":"KeyImPaCT","url":"https://clinicaltrials.gov/study/NCT03516981","created_at":"2021-01-18T17:18:40.896Z","updated_at":"2024-07-02T16:35:17.597Z","phase":"Phase 2","brief_title":"A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)","source_id_and_acronym":"NCT03516981 - KeyImPaCT","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab (MK-4280) • quavonlimab (MK-1308) • favezelimab/pembrolizumab (MK-4280A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 06/28/2025","primary_completion_date":" 06/28/2025","study_txt":" Completion: 06/28/2025","study_completion_date":" 06/28/2025","last_update_posted":"2024-02-26"}]